Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S018000
Reexamination Certificate
active
07973047
ABSTRACT:
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula Iwherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
REFERENCES:
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5712130 (1998-01-01), Hajko et al.
patent: 5942400 (1999-08-01), Anderson et al.
patent: 6864290 (2005-03-01), Schostarez et al.
patent: 6982264 (2006-01-01), John et al.
patent: 6992103 (2006-01-01), Faller et al.
patent: 7067542 (2006-06-01), Schostarez et al.
patent: 7074799 (2006-07-01), Bakthavatchalam et al.
patent: 7109217 (2006-09-01), Coburn et al.
patent: 7115652 (2006-10-01), Yang
patent: 7115747 (2006-10-01), Reeder et al.
patent: 7132568 (2006-11-01), Yang et al.
patent: 7176242 (2007-02-01), John et al.
patent: 7223774 (2007-05-01), Aquino et al.
patent: 7244755 (2007-07-01), Fisher et al.
patent: 7253198 (2007-08-01), Demont et al.
patent: 7291620 (2007-11-01), Coburn et al.
patent: 7312360 (2007-12-01), TenBrink et al.
patent: 7348448 (2008-03-01), Nantermet et al.
patent: 7351738 (2008-04-01), Pulley et al.
patent: 7371853 (2008-05-01), Coburn et al.
patent: 2007/0185103 (2007-08-01), Albrecht
patent: 00/17369 (2000-03-01), None
patent: 01/70671 (2001-09-01), None
patent: 02/02505 (2002-01-01), None
patent: 03/002518 (2003-01-01), None
patent: 03109559 (2003-06-01), None
patent: 03166580 (2003-09-01), None
patent: 2004180939 (2004-09-01), None
patent: 2004/099376 (2004-11-01), None
patent: 2005027007 (2005-02-01), None
patent: 2005038019 (2005-02-01), None
patent: 2005054690 (2005-03-01), None
patent: WO 2005035535 (2005-04-01), None
patent: 2005267199 (2005-12-01), None
patent: 2006211740 (2006-09-01), None
patent: 2006229302 (2006-10-01), None
patent: 2006241133 (2006-10-01), None
Submitted to U.S. Appl. No. 11/595,187.
Berge, et al., “Pharmaceutical Salts”, J. of Pharmaceutical Sciences, 66(1), 1-19 (1977).
Citron, M., “β-Secretase Inhibition for the Treatment of Alzheimer's Disease—Promise and Challenge”, Trends in Pharmacological Sciences, 25(2), 92-97 (2004).
Corey, et al., “The Application of a Mechanistic Model Leads to the Extension of the Sharpless Asymmetric Dihydroxylation to Allylic 4-Methoxybenzoates and Conformationally Related Aine and Homoallylic Alcohol Derivatives”, J. of Am. Chem. Soc., 117, 10805-10816 (1995).
Joachim, et al., “The Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer Disease”, Alzheimer Disease and Associated Disorders, 6(1), 7-34 (1992).
Luo, et al., “Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation”, Nature Neuroscience, 4(3), 231-232 (2001).
Reynaud, et al., “New Synthesis of the Thiazole Ring”, Bulletin de la Societe chimique de France, 1735-1738 (1962).
Sabbagh, et al.,“β-Amyloid and Treatment Opportunities for Alzheimer's Disease”, Alzheimer's Disease Review, 3, 1-19 (1998).
Selkoe, D.M., “The Molecular Pathology of Alzheimer's Disease”, Neuron, 6, 487-498 (1991).
Seubert, et al., “Isolation and Quantification of Soluble Alzheimer's β-Peptide from Biological Fluids”, Nature, 359, 325-327 (1992).
Sinha, et al., “Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain”, Nature, 402, 537-540 (1999).
Strangeland, et al., “Use of Thiazoles in the Halogen Dance Reaction: Application to the Total Synthesis of WS75624 B”, J. Org. Chem., 69, 2381-2385 (2004).
Albrecht Brian K.
Bartberger Michael D.
Brown James
Brown Ryan
Chaffee Stuart C.
Amgen Inc.
Prabhakar Reddy G.
Solola Taofiq A
LandOfFree
Beta-Secretase modulators and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-Secretase modulators and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-Secretase modulators and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730247